{"id":12,"date":"2023-01-05T17:58:09","date_gmt":"2023-01-05T17:58:09","guid":{"rendered":"https:\/\/pkudsehcp-dev-001.azurewebsites.net\/en-us\/phenylketonuria\/?page_id=12"},"modified":"2024-07-31T13:19:53","modified_gmt":"2024-07-31T13:19:53","slug":"home","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/pku\/","title":{"rendered":"Home"},"content":{"rendered":"
PKU is characterized by a deficiency in phenylalanine hydroxylase (PAH) activity resulting in an excess of the amino acid phenylalanine (Phe) in the blood and brain. If not adequately controlled, Phe becomes neurotoxic and disrupts normal neurophysiology.1,2<\/sup><\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n This site has been developed for healthcare professionals who treat people with phenylketonuria (PKU). The site is meant to educate and heighten awareness of the PKU burden of illness, the impact of elevated phenylalanine (Phe), as well as the continued unmet need.1,2<\/sup><\/p>\n <\/div>\n\n PKU is an autosomal recessive inborn error of Phe metabolism, which can have significant neurodevelopment sequelae.1-3<\/sup><\/p>\n Genetics and Pathophysiology <\/a><\/p>\n <\/div>\n<\/div>\n\n 67% of adults with PKU are above guideline Phe target ranges, increasing the severity of neuropsychological symptoms and negatively impacting life trajectory.4<\/sup><\/p>\n Lifelong burden <\/a><\/p>\n <\/div>\n<\/div>\n\n <\/div>\n <\/figure>\n <\/div>\n
What causes PKU?\n<\/h3>\n
<\/div>\n <\/figure>\n <\/div>\n
Phe control diminishes with age2,4<\/sup>\n<\/h3>\n
<\/div>\n <\/figure>\n <\/div>\n